Quick answer: what is IGF-1 DES?
IGF-1 DES (DES(1-3)IGF-1) is a shortened, more potent variant of insulin-like growth factor 1, marketed for muscle growth.
New to peptides? Start with what are peptides? and how do peptides work?
Quick facts
- Class
- Truncated IGF-1 analog
- Related to
- IGF-1 and IGF-1 LR3
- Studied for
- Tissue and muscle growth (animal / cell models)
- Evidence level
- Preclinical; no human performance trials
- Approval
- Not FDA-approved; sold as a research chemical
- Structure
- IGF-1 lacking first 3 amino acids
- Related compound
- IGF-1 LR3
- Human evidence
- None (animal / cell studies only)
Key takeaways
- Missing its first three amino acids, it escapes the binding proteins that normally restrain IGF-1, leaving more of it free to act.
- It is studied only in animals and cells; there are no human trials for muscle building or performance.
- It is not FDA-approved, is sold as a research chemical, and IGF-1 analogs are banned in sport.
Overview
IGF-1 DES, written more precisely as DES(1-3)IGF-1, is a naturally occurring variant of insulin-like growth factor 1 that is missing the first three amino acids of the standard molecule. It is found in human and bovine tissue, and it is produced by cleavage of full-length IGF-1 rather than being a purely synthetic invention.
Why a three-amino-acid deletion matters so much
Removing those three residues has an effect out of proportion to its size. The truncation dramatically reduces the peptide's affinity for the IGF-binding proteins that normally sequester circulating IGF-1, so a far greater fraction remains free to activate the receptor. In laboratory settings this makes DES(1-3)IGF-1 substantially more potent than intact IGF-1 — not because it activates the receptor more strongly, but because more of it reaches the receptor at all.
How it is marketed, and what is actually known
In bodybuilding contexts, IGF-1 DES is promoted for localized muscle growth, on the claim that injecting near a trained muscle produces growth confined to that area. That claim rests on the peptide's short duration and high local potency in animal tissue. It has not been tested in humans for this purpose.
The evidence base is entirely preclinical — animal models and cell culture. There are no human trials of IGF-1 DES for muscle growth, performance, or any other application. It is not an approved drug anywhere and is sold only as a research chemical.
How it works
The binding-protein brake
Most circulating IGF-1 is not free. It is bound to a family of IGF-binding proteins, chiefly IGFBP-3, which act as a reservoir and a brake — extending the hormone's half-life while limiting how much is available to act at any moment. This is a deliberate regulatory mechanism: IGF-1 is a potent growth signal and the body constrains it.
What the truncation does
The first three amino acids of IGF-1 are important for binding-protein recognition. Removing them sharply lowers affinity for IGFBPs while leaving receptor binding largely intact. The practical consequence is more free peptide, faster access to the IGF-1 receptor, and a shorter duration of action, since the binding proteins also protected it from clearance.
Downstream signaling
Once it engages the IGF-1 receptor, the signaling is the same as for normal IGF-1: activation of the PI3K/Akt/mTOR pathway that drives protein synthesis and cell growth, and the MAPK pathway associated with proliferation. In skeletal muscle these pathways promote hypertrophy and can activate satellite cells involved in repair.
Where the localization claim comes from — and its limits
A short-acting, highly potent peptide injected into tissue plausibly acts more locally than a long-acting one that distributes systemically. That is a reasonable inference, not a demonstrated fact in humans. Diffusion, local blood flow, and absorption into the general circulation all work against strict localization, and no human study has measured how confined the effect actually is.
Research & evidence
What the animal literature shows
DES(1-3)IGF-1 has been studied in animal models of tissue growth and repair, where it has generally shown greater potency than intact IGF-1. Reported findings include enhanced intestinal adaptation after bowel resection, growth effects in rats with reduced kidney mass, and effects on growth in various developmental models. In cell culture it activates the growth-signaling machinery of skeletal muscle as expected.
Notably, much of this literature exists because DES(1-3)IGF-1 is a useful research tool for studying IGF-1 biology without binding-protein interference — not because anyone was developing it as a muscle-building therapy.
What is missing
There are no human trials of IGF-1 DES for muscle growth, athletic performance, body composition, or injury recovery. There are no human pharmacokinetic studies establishing how it behaves after injection, no dose-finding work, and no controlled safety data. Marketing claims about localized hypertrophy are extrapolations from rodent potency data across a very large gap.
Comparison with IGF-1 LR3
The other modified IGF-1 circulating in this space, IGF-1 LR3, takes a different approach: it adds a 13-amino-acid extension and substitutes one residue, also reducing binding-protein affinity but producing a much longer-acting molecule. IGF-1 DES is more potent but shorter-acting; LR3 is longer-acting. Both are unapproved research chemicals with no human efficacy evidence, and the choice between them is a matter of marketing narrative rather than clinical data.
Safety & legal status
The honest position on safety
Human safety data do not exist. This should be stated as an absence of information rather than reassurance — the risk profile is unquantified, not favorable.
The theoretical concerns follow from what IGF-1 signaling does:
- Hypoglycemia. IGF-1 has structural similarity to insulin and can activate insulin receptors at sufficient concentration, potentially lowering blood sugar unpredictably.
- Cell-growth concerns. Chronically amplifying a potent proliferative signal is the general worry with any IGF-1 analog. Epidemiological work has linked higher circulating IGF-1 with increased risk of certain cancers, which does not establish that exogenous administration causes cancer but is a reasonable basis for caution.
- Unwanted tissue growth in organs and tissues other than the intended target, since receptors are widespread.
- Product risk. Research-chemical peptides are not manufactured to pharmaceutical standards; independent testing of this market has repeatedly found incorrect identity, low purity, and contamination. What is in the vial is itself an unknown.
Legal and sporting status
IGF-1 DES is not FDA-approved for any use in humans. It is sold labeled for research use only, which is a regulatory category for laboratory materials — not an authorization for human use. IGF-1 and its analogs are explicitly prohibited in sport by the World Anti-Doping Agency at all times, in and out of competition.
We do not publish dosing information for unapproved compounds. See our guides to IGF-1 and IGF-1 LR3 for related context, and our explainer on what research peptides actually are.
Frequently asked questions
What is IGF-1 DES?
IGF-1 DES, or DES(1-3)IGF-1, is a naturally occurring variant of insulin-like growth factor 1 that is missing the first three amino acids. This makes it evade IGF-binding proteins and act more potently in tissue, which is why it is circulated in bodybuilding for muscle growth.
How is IGF-1 DES different from IGF-1 LR3?
Both are modified IGF-1 forms designed to evade binding proteins and act more potently and, for LR3, more durably. IGF-1 DES is a truncated version (missing three amino acids), while LR3 is a lengthened, substituted version. Neither has human performance evidence.
Does IGF-1 DES build muscle?
In animal and cell studies it potently activates muscle growth pathways, but there are no controlled human trials showing it builds muscle or improves performance. Claims of localized muscle growth are extrapolated from animal data, not demonstrated in people.
Is IGF-1 DES safe or legal?
Its human safety is unknown, and strongly driving IGF-1 growth signaling carries theoretical risks including effects on blood sugar and abnormal cell growth. It is not FDA-approved, is sold only as a research chemical, and IGF-1 analogs are banned in sport by WADA.
References
Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.
- Martin AA, Tomas FM, Owens PC, et al. IGF-I and its variant, des-(1-3)IGF-I, enhance growth in rats with reduced renal mass. Am J Physiol. 1991. Peer-reviewed study
- Lemmey AB, Martin AA, Read LC, et al. IGF-I and the truncated analogue des-(1-3)IGF-I enhance growth in rats after gut resection. Am J Physiol. 1991. Peer-reviewed study
- Ballard FJ, Wallace JC, Francis GL, et al. Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I. Int J Biochem Cell Biol. 1996. Peer-reviewed study
- Li M, Li C, Parkhouse WS. Age-related differences in the des IGF-I-mediated activation of Akt-1 and p70 S6K in mouse skeletal muscle. Mech Ageing Dev. 2003. Peer-reviewed study